Eli Lilly (NYSE:LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's (NVO ...

Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England ...

TOKYO -- U.S. drugmaker Eli Lilly has released its Zepbound obesity medication in Japan, targeting the millions said to suffer from the "hidden" scourge of buildups of visceral fat. "We believe ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...